Fig. 4

Reduced c-Myc protein expression by matrine in DLBCL cells. a-b SU-DHL-16 and OCI-LY3 cells were exposed to 1.76 mM and 4.1 mM matrine for 48 h, respectively, and c-Myc protein levels were measured by western blot. Full-length blots are presented in Supplementary Figure 3. c-d c-Myc mRNA levels in SU-DHL-16 and OCI-LY3 cells were determined by quantitative RT-PCR at 24 h after different concentrations of matrine treatment (n.s., not significant; **p < 0.01 compared to 0 mM group). e-f CHX chase assay for the half-life of c-Myc. SU-DHL-16 and OCI-LY3 cells were treated with or without 1.76 mM and 4.1 mM matrine for 12 h, respectively. Cells were then treated with CHX for the indicated minutes, and western blotting was performed. Full-length blots are presented in Supplementary Figure 4. g-h c-Myc levels were quantified relative to GAPDH levels and graphed as percent c-Myc protein remaining after CHX treatment. Half-lives of c-Myc were calculated from exponential line equations and shown for each treat. Analyses in triplicates